Cargando…

Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities

Sickle cell disease (SCD) is a genetic disorder that affects millions of individuals worldwide. Chronic anemia, hemolysis, and vasculopathy are associated with SCD, and their role has been well characterized. These symptoms stem from hemoglobin (Hb) polymerization, which is the primary event in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alramadhani, Dina, Aljahdali, Anfal S., Abdulmalik, Osheiza, Pierce, B. Daniel, Safo, Martin K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266828/ https://www.ncbi.nlm.nih.gov/pubmed/35806451 http://dx.doi.org/10.3390/ijms23137448

Ejemplares similares

Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease
por: Alhashimi, Rana T., et al.
Publicado: (2022)

Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease
por: Abdulmalik, Osheiza, et al.
Publicado: (2017)

Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease
por: Sun, Kaiqi, et al.
Publicado: (2017)

A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells
por: Nakagawa, Akito, et al.
Publicado: (2018)

An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling
por: Omar, Abdelsattar M., et al.
Publicado: (2020)

Identification of a Small Molecule that Increases Hemoglobin Oxygen Affinity and Reduces SS Erythrocyte Sickling
por: Nakagawa, Akito, et al.
Publicado: (2014)

Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease
por: Huang, Boshi, et al.
Publicado: (2022)

X-ray crystallography and sickle cell disease drug discovery—a tribute to Donald Abraham
por: Donkor, Akua K., et al.
Publicado: (2023)

Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients
por: Rab, Minke A.E., et al.
Publicado: (2019)

Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia
por: Abdulmalik, Osheiza, et al.
Publicado: (2021)

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions
por: Abdulmalik, Osheiza, et al.
Publicado: (2020)

Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease
por: Ahmed, Tarek A., et al.
Publicado: (2021)

Docking and Molecular Dynamic Investigations of Phenylspirodrimanes as Cannabinoid Receptor-2 Agonists
por: Omar, Abdelsattar M., et al.
Publicado: (2022)

Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer
por: Corchado-Cobos, Roberto, et al.
Publicado: (2022)

Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology
por: Shen, Xinpeng, et al.
Publicado: (2020)

Molecular insight into 2-phosphoglycolate activation of the phosphatase activity of bisphosphoglycerate mutase
por: Aljahdali, Anfal S., et al.
Publicado: (2022)

Pathophysiological insights in sickle cell disease
por: Odièvre, Marie-Hélène, et al.
Publicado: (2011)

Metabolic Reprogramming in Kidney Diseases: Evidence and Therapeutic Opportunities
por: Li, Yin, et al.
Publicado: (2021)

Editorial: Relevance of Steroid Biosynthesis, Metabolism and Transport in Pathophysiology and Drug Discovery
por: Rižner, Tea Lanišnik
Publicado: (2019)

Inhibition of the Aquaporin-1 Cation Conductance by Selected Furan Compounds Reduces Red Blood Cell Sickling
por: Chow, Pak Hin, et al.
Publicado: (2022)

What's New in the Pathophysiology of Sickle Cell Disease?
por: Adekile, Adekunle D.
Publicado: (2013)

Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin
por: Omar, Abdelsattar M., et al.
Publicado: (2016)

Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde
por: Alhashimi, Rana T., et al.
Publicado: (2023)

AI in drug discovery: Applications, opportunities, and challenges
por: Bittner, Martin-Immanuel, et al.
Publicado: (2022)

Deubiquitylating enzymes and drug discovery: emerging opportunities
por: Harrigan, Jeanine A., et al.
Publicado: (2017)

Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease
por: Vunnam, Nagamani, et al.
Publicado: (2022)

Tumor Metabolome: Therapeutic Opportunities Targeting Cancer Metabolic Reprogramming
por: Márquez, Javier, et al.
Publicado: (2021)

Advanced pathophysiology mimicking lung models for accelerated drug discovery
por: Phan, Thanh Huyen, et al.
Publicado: (2023)

A Reverse Time-Course Method for Transcriptional Chase Analyses of mRNA Half-Lives in Cultured Cells
por: Abdulmalik, Osheiza, et al.
Publicado: (2012)

Emerging target discovery and drug repurposing opportunities in chordoma
por: Freed, Daniel M., et al.
Publicado: (2022)

Boosting NAD: An opportunity for metabolic reprogramming of Th17 cells in psoriatic disease
por: Reali, Eva
Publicado: (2023)

Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment
por: Inusa, Baba P. D., et al.
Publicado: (2019)

Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology
por: Lizarralde-Iragorri, Maria A., et al.
Publicado: (2020)

The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies
por: Blanco-González, Alexandre, et al.
Publicado: (2023)

Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy
por: Sun, Nai-Yun, et al.
Publicado: (2020)

Natural products in drug discovery: advances and opportunities
por: Atanasov, Atanas G., et al.
Publicado: (2021)

An Update on CFTR Drug Discovery: Opportunities and Challenges
por: D’Ursi, Pasqualina, et al.
Publicado: (2022)

Deuterium in drug discovery: progress, opportunities and challenges
por: Di Martino, Rita Maria Concetta, et al.
Publicado: (2023)

Editorial: Molecular Mechanisms Controlling the Metabolic Reprogramming of Immune Cells Under Pathophysiological Conditions
por: Fitzpatrick, Susan F., et al.
Publicado: (2020)

Sickling Cells, Cyclic Nucleotides, and Protein Kinases: The Pathophysiology of Urogenital Disorders in Sickle Cell Anemia
por: Claudino, Mário Angelo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7q3or3vc7vah4a6pf18aci1bbk